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Clonal complex 59 (CC59) community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) strains
were characterized using pulsed-field gel electrophoresis, spa typing, multilocus sequence typing, diagnostic DNA
microarrays, and PCRs targeting staphylococcal cassette chromosome mec (SCCmec) elements and Panton-Valen-
tine leukocidin (PVL). Six distinct groups within CC59 were characterized. At least seven different variants of
SCCmec elements were identified (IVa [2B], IVb [2B], IVd [2B], IV variant [2B], IVa [2B&5], V variant [5C2], and
V [5C2&5]). (The structural type is indicated by a Roman numeral, with a lowercase letter indicating the subtype,
and the ccr complex and the mec complex are indicated by an Arabic numeral and an uppercase letter, respectively.
Where there is an extra ccr element, this is indicated by “&” and an Arabic numeral designating the ccr type.) The
first group is similar to the American sequence type 59 (ST59) MRSA-IV CA-MRSA strain USA1000. The second
group includes a PVL-negative ST87 strain with an SCCmec element of subtype IVb (2B). The third group comprises
PVL-variable ST59 MRSA-IV strains harboring multiple SCCmec IV subtypes. PVL-negative ST59 MRSA strains
with multiple or composite SCCmec elements (IVa [2B&5]) form the fourth group. Group 5 corresponds to the
internationally known “Taiwan clone,” a PVL-positive strain with a variant SCCmec element (V [5C2&5]). This
strain proved to be the most common CC59 MRSA strain isolated in Western Australia. Finally, group 6 encom-
passes the ST59 MRSA-V variant (5C2). The differentiation of CC59 into groups and strains indicates a rapid
evolution and spread of SCCmec elements. Observed differences between groups of strains as well as intrastrain
variability within a group facilitate the tracing of their spread.
Several well-characterized community-associated methicil-
lin-resistant Staphylococcus aureus (CA-MRSA) strains pre-
dominate in different regions of the world. Many of these
strains harbor the bicomponent Panton-Valentine leukocidin
(PVL). Sequence type 8 (ST8) MRSA-IV (USA300), ST80
MRSA-IV, and ST93 MRSA-IV are the major CA-MRSA
strains reported to occur in the United States, Europe, and
Australia, respectively. In the Asia Pacific region, a distinct
genotype, clonal complex 59 (CC59)/ST59, has become wide-
spread. ST59 CA-MRSA strains are an important cause of
morbidity in Taiwan (1, 13, 17, 25, 29) This so-called “Taiwan
clone” has acquired a novel type V staphylococcal cassette
chromosome mec (SCCmec) element (V [5C2&5], also known
as VT) and ermB, a macrolide-lincosamide-streptogramin B
resistance gene (28) frequently reported to be present in strep-
tococci and other bacteria. Its properties have recently been
described in detail (24). ST59 MRSA-V and other CC59
strains have now been reported to occur in several countries,
including the United States (USA1000) (6), Sweden (11), Ger-
many (20), the United Kingdom (19), Vietnam (26), and Aus-
tralia (22).
In Western Australia (WA), all MRSA strains are referred
to the state’s central typing reference laboratory (the Gram-
Positive Bacteria Typing and Research Unit) for molecular
characterization (5). Multiple CC59 strains, colloquially char-
acterized as WA MRSA-9, -15, -24, -52, -55, -56, and -73, have
been identified. They differ from each other in ST designation,
pulsed-field gel electrophoresis (PFGE) pattern, SCCmec ele-
ment, and PVL carriage.
To better understand the molecular epidemiology of this
clonal complex, all CC59 MRSA strains isolated in Western
Australia were examined using PFGE, spa typing, multilocus
sequence typing (MLST), diagnostic DNA microarrays, and
PCRs targeting SCCmec elements and PVL.
MATERIALS AND METHODS
Isolates and patients. From July 2003 to June 2008, 43 MRSA strains from 40
individuals living in WA were characterized as CC59 MRSA by the Gram-
Positive Bacteria Typing and Research Unit. One person yielded three isolates
(WA MRSA-15 04-16657, 05-17619, and 06-17484) over a 3-year period, and a
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second yielded two isolates (WA MRSA-9 06-17363 and 07-17830) over a 2-year
period. Three isolates (WA MRSA-52 07-15076, 07-16295, and 07-16320) were
obtained from three family members over a 12-month period. Isolates were
recovered from 33 skin and soft tissue infections and seven nasal screening
swabs.
Control strains. Two reference strains of USA1000 ST59 MRSA-IV
(NARSA483 and NARSA676) were obtained from the Network on Antimicro-
bial Resistance in Staphylococcus aureus (NARSA) and have been included in
this study for comparison.
Susceptibility testing. An antibiogram was performed by disk diffusion on
Mueller-Hinton agar according to the Clinical and Laboratory Standards Insti-
tute (CLSI) recommendations (3). A panel of eight antimicrobial drugs, i.e.,
erythromycin (15 g), tetracycline (30 g), trimethoprim (5 g), ciprofloxacin (5
g), gentamicin (10 g), rifampin (5 g), fusidic acid (10 g), and mupirocin (5
g), was tested. CLSI interpretive criteria (4) were used for all drugs except
fusidic acid (2) and mupirocin (9).
PFGE. Electrophoresis of chromosomal DNA was performed as previously
described (23), using a contour-clamped homogeneous electric field (CHEF) DR
III system (Bio-Rad Laboratories Pty Ltd). Chromosomal patterns were exam-
ined visually, scanned with a Quantity One device (Bio-Rad Laboratories Pty
Ltd), and digitally analyzed using FPQuest (Bio-Rad Laboratories). CHEF pat-
terns were grouped according to the criteria of Tenover et al. (27), and a
dendrogram similarity of 80% or greater was used to assign strain relatedness. S.
aureus strain NCTC 8325 was used as a reference strain.
MLST and spa typing. Chromosomal DNA for MLST and spa typing was
prepared using a DNeasy tissue kit (Qiagen Pty Ltd).
MLST was performed as specified by Enright et al. (7). The method involves
bidirectional sequencing of 450- to 500-bp internal fragments of seven house-
keeping genes obtained by PCR using highly conserved primer pairs. Each allele
sequence is assigned a number by the curator of the MLST database (http:
//saureus.mlst.net), and the allelic profile determines the sequence type (ST).
Allelic profiles can be compared using the BURST (based upon related sequence
types) program (http://linux.mlst.net/burst.htm). Clusters of single-locus variants
(SLVs) and double-locus variants are referred to as clonal clusters.
To assign an ST, sequences were compared with the sequences on the MLST
website. By use of the MLST database, clones were subsequently grouped into
CC59.
spa typing, a DNA sequence-based analysis of the protein A gene variable
region, was performed as previously described (10) using the nomenclature as
described on the Ridom website (http://spa.ridom.de/).
PVL. PCR for the detection of PVL determinants was performed as previously
described (8).
SCCmec typing. SCCmec is a mobile genetic element that carries the mecA
gene, which encodes broad-spectrum beta-lactam resistance, and unique site-
specific recombinases designated cassette chromosome recombinases (ccr).
SCCmec elements are classified into types and subtypes by a hierarchical system
(15). Types are defined by the combination of the ccr gene complex (types 1 to
5, represented by the ccr gene allotypes [ccrA1, ccrA2, ccrA3, and ccrA4; ccrB1,
ccrB2, ccrB3, and ccrB4; and ccrC1]) and the mec gene complex (classes A, B, C1,
and C2). The SCCmec element also contains three nonessential components
known as the “J regions.” Variations in the J regions within the same mec-ccr
complex are used for defining SCCmec subtypes.
SCCmec was typed by PCR using the following strategy. The structural archi-
tecture and the mec complex were determined using primers described by Zhang
et al. (30). SCCmec type IV was further subtyped using published primers (18).
Cassette chromosome recombinase (ccr) typing and ccrC1 allele 2 and 8 allotyp-
ing were performed as published previously (12, 16). Nontypeable strains and the
type V SCCmec were characterized using previously published primers (15). An
ISSau4-like transposase (GenBank accession no. DQ680163) insertion in open
reading frame (ORF) V011 (GenBank accession no. AB12129) of the type V
SCCmec was detected by the production of a ca. 1,600-bp PCR product rather
than the characteristic 325-bp product in the multiplex reaction performed by
Zhang et al. (30) and confirmed by sequencing. SCCmec nomenclature is used as
proposed by the International Working Group on the Classification of Staphy-
lococcal Cassette Chromosome Elements (IWG-SCC) (15). Briefly, the struc-
tural type is indicated by a Roman numeral, with a lowercase letter indicating the
subtype, and the ccr complex and the mec complex are indicated by an Arabic
numeral and an uppercase letter, respectively. Where there is an extra ccr
element, this is indicated by “&” and an Arabic numeral designating the ccr type.
DNA microarray. The DNA microarray used for this study covered 334 target
sequences corresponding to 185 distinct genes and their allelic variants. A com-
plete list of targets has been provided previously (20, 21). Target genes included
species markers, virulence factors, resistance genes, staphylococcal superantigen-
like or exotoxin-like genes (set or ssl genes), and genes encoding adhesion
proteins, as well as markers for accessory gene regulator (agr) alleles and capsule
types. With regard to SCCmec typing, the array included probes for mecA, ugpQ
(GenBank accession no. BA000018.3, locus tag SA0036), mecI (BA000018.3,
SA0040), xylR (BA000018.3, SA0041), the dcs region (BA000018.3, SA0024
[EMBL accession no. Q9XB68]), and two probes for mecR (BA000018.3,
SA0039). The last two probes allowed detection and discrimination of untrun-
cated mecR and mecR, respectively. Recombinase genes ccrA1, ccrB1, ccrA2,
ccrB2, ccrA3, ccrB3, ccrA4, ccrB4, and ccrC1 were also covered. A gene for a
“hypothetical protein” accompanying ccrC1 was also included, and alleles from
strain 85-2082 (GenBank accession no. AB037671.1, nucleotides 61250 to 62893)
and strain MRSAZH47 (GenBank accession no. AM292304.1, nucleotides 5654
to 7273) were distinguished. The mercury resistance and kdp operons were also
included, but they are not relevant for the CC59 strains discussed in this study.
Arrays and reagents were obtained from CLONDIAG. The principle of the
assay and related procedures have previously been described in detail (20, 21).
Briefly, DNA was obtained by enzymatic lysis of overnight cultures. All targets
were simultaneously amplified by linear PCR, and the products were labeled by
the incorporation of biotin–16-dUTP during the reaction. The labeled sample
was then hybridized to the array, followed by washing steps and the addition of
a blocking reagent. Horseradish peroxidase-streptavidin conjugate was added to
the array, followed again by incubation and washing. Finally, Seramun Green
precipitating dye (Seramun, Heidesee, Germany) was added. An image of the
array was recorded and analyzed using a dedicated reader and software.
SplitsTree analysis. To analyze similarities between DNA microarray profiles,
SplitsTree software (14) was used. DNA microarray results for relevant genes
(see the legend for Fig. 2) were converted into strings of information which were
handled as “sequences,” using “A” for “positive” and “T” for “negative.” These
“sequences” were used for tree construction using SplitsTree 4.10 (character
transformation, uncorrected P; distance transformation, Neighbor-Net; and vari-
ance, ordinary least squares).
RESULTS
Antibiogram analysis, PVL PCR, PFGE, spa typing, MLST,
SCCmec typing, and DNA microarray analysis (data not
shown) were performed on all isolates (Tables 1 and 2).
PFGE identified seven WA CC59 CA-MRSA strains: WA
MRSA-9, -15, -24, -52, -55, -56, and -73 (Fig. 1).
Shared properties of CC59 MRSA isolates. All isolates were
agr group I and capsule type 8 and carried the gamma-hemo-
lysin genes lukF, lukS, and hlgA, as well as the hl (GenBank
accession no. CP000046.1, locus tag SACOL0921), hla, hld,
and hlIII hemolysin genes. Three out of five probes for beta-
hemolysin yielded signals, which could be interpreted as an
indication of an as yet unsequenced allelic variant. Leukocidin
genes lukD and lukE were not detected. All isolates lacked
protease genes splA, splB, and splE but harbored aur, sspA,
sspB, and sspP. The carriage of set and ssl genes was uniform
among all isolates, including the presence of setC, ssl1 (in a
Mu50/N315-like allele), ssl3, ssl4, ssl5 (an unsequenced allele
giving signals with a probe derived from CC1/5/8 sequences as
well as with another one based on RF122), ssl7, ssl8, ssl9, ssl10,
and setB1 to setB3. The probe for ssl2 gave weaker or variable
results, indicating another as yet unsequenced allelic variant.
The biofilm operon icaACD was present. The gene for a
biofilm-associated protein, bap, was absent.
Genes encoding MSCRAMMs (microbial surface compo-
nents recognizing adhesive matrix molecules), bbp, clfA, clfB,
ebh, ebpS, eno, fib, fnbA, fnbB, map, sasG, sdrC, sdrD, and vwb
were detected in all isolates. The gene for collagen-binding
adhesin (cna) was absent.
Carriage of resistance genes, PVL, beta-hemolysin integrat-
ing phages, and superantigens was variable.
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TABLE 1. Antibiogram results, PVL PCR results, PFGE patterns, spa types, MLST results, and SCCmec types for the CC59 MRSA isolates




PFGE pattern spa sequence spatype MLST sequence ST
SCCmec
type
Group 1, “WA MRSA-73”
05-16512 Colonization N WA MRSA-73 04 t528 19-23-15-2-19-20-15 59 IVb (2B)
Group 2, “WA MRSA-24”
04-17626 SSTIb Eryr N WA MRSA-24 04-20-17-20-17-31-16-34 t216 19-23-15-2-41-20-15 87 IVb (2B)
06-15325 SSTI Eryr N WA MRSA-24 04-20-17-20-17-31-16-34 t216 19-23-15-2-41-20-15 87 IVb (2B)
06-16824 SSTI Eryr N WA MRSA-24 04-20-17-20-17-31-16-34 t216 19-23-15-2-41-20-15 87 IVb (2B)
Group 3, “WA
MRSA-55/56”
06-17947 SSTI Eryr Tetr P WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVa (2B)
06-16367 SSTI Eryr Tetr P WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVa (2B)
07-15432 SSTI Eryr Tetr P WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVa (2B)
07-15760 SSTI Eryr Tetr P WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVa (2B)
08-16180 SSTI Eryr Tetr P WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVd (2B)
08-17668 Colonization Eryr N WA MRSA-55 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVv (2B)
07-15443 SSTI Eryr P WA MRSA-56 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 IVa (2B)
Group 4, “WA MRSA-15”
03-17565 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
04-16557 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
04-17489 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
05-17037 SSTI Eryr Tetr N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
05-17619 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
06-15513 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
06-17484 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
07-19251 SSTI Eryr N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
08-15202 SSTI N WA MRSA-15 04-20-17-20-31-16-34 t976 19-23-15-2-19-20-15 59 IVa (2B&5)
Group 5, “WA MRSA-9/
52,” or “Taiwan
clone”
06-15672 SSTI Eryr Tetr P WA MRSA-9 04-20-17-25-34 t441 19-23-15-2-19-20-15 59 V (5C2&5)
06-17363 SSTI Eryr Tetr P WA MRSA-9 04-20-17-25-34 t441 19-23-15-2-19-20-15 59 V (5C2&5)
07-16447 SSTI Eryr Tetr P WA MRSA-9 04-20-17-25-34 t441 19-23-15-2-19-20-15 59 V (5C2&5)
07-17830 SSTI Eryr Tetr P WA MRSA-9 04-20-17-25-34 t441 19-23-15-2-19-20-15 59 V (5C2&5)
03-16672 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
04-16811 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
04-17021 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
05-15724 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
07-15919 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
07-16753 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
07-16861 SSTI Eryr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
07-18714 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
08-15039 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
08-18104 SSTI Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
08-18190 Colonization Eryr Tetr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-2-19-20-15 59 V (5C2&5)
07-17677 Colonization Eryr P WA MRSA-9 04-20-17-20-17-25-34 t437 19-23-15-48-19-20-15 338 V (5C2&5)
07-15076 Colonization Eryr P WA MRSA-52 04-20-17-20-17-34 t1950 113-23-15-2-19-20-15 952 V (5C2&5)
07-16295 Colonization Eryr P WA MRSA-52 04-20-17-20-17-34 t1950 113-23-15-2-19-20-15 952 V (5C2&5)
07-16320 Colonization Eryr P WA MRSA-52 04-20-17-20-17-34 t1950 113-23-15-2-19-20-15 952 V (5C2&5)
07-16355 SSTI Eryr P WA MRSA-9 04-20-16-34 t2365 19-23-15-2-19-20-15 59 V (5C2&5)
Group 6, “WA MRSA-9”
05-17759 SSTI N WA MRSA-9 04-20-17-31-16-34 t316 19-23-15-2-19-20-15 59 Vv (5C2)
08-15683 SSTI Eryr N WA MRSA-9 04-20-17-31-16-34 t316 19-23-15-2-19-20-15 59 Vv (5C2)
06-18653 SSTI Cipr N WA MRSA-9 04-20-17-25-34 t441 19-23-15-2-19-20-15 59 Vv (5C2)
NARSA control strains,
“USA1000”
NARSA483 Eryr P USA1000 04-20-17-31-16-34 t316 19-23-15-2-19-20-15 59 IVa (2B)
NARSA676 P USA1000 04-20-17-20-17-31-16-34 t216 19-23-15-2-19-20-15 59 IVa (2B)
a Group 1, PVL-negative ST59 MRSA-IVb (2B) (ccrA2B2 and mec complex class B); group 2, PVL-negative ST87 (59SLV) MRSA-IVb (2B) (ccrA2B2 and mec
complex class B); group 3, PVL-variable ST59 MRSA-IVa, -IVd, and -IVv (2B) (ccrA2B2 and mec complex class B); group 4, PVL-negative ST59 MRSA-IVa (2B&5)
(ccrA2B2, mec complex class B, and ccrC1); group 5, PVL-positive ST59/338 (59SLV)/952 (59SLV) MRSA-V (5C2&5) (mec complex class C2 and ccrC1); group 6,
PVL-negative ST59 MRSA-Vv (5C2) (mec complex class C2 and ccrC1); NARSA control strains, PVL-positive ST59 MRSA-IVa (2B) (ccrA2B2 and mec complex
class B).
b SSTI, skin and soft tissue infection.
c Eryr, erythromycin resistant; Tetr, tetracycline resistant; Cipr, ciprofloxacin resistant.
d N, negative; P, positive.
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DNA microarray-based analysis of the CC59 isolates clus-
tered them into six groups (Fig. 2).
Group 1, “WA MRSA-73” (PVL-negative ST59 MRSA-IVb
[2B]). “WA MRSA-73” (isolate 05-16512) is an ST59/spa type
t528 strain that has acquired an SCCmec IVb (2B) (ccrA2B2
and mec complex class B) element. Although lacking PVL, this
strain has a DNA microarray profile similar to that of
the NARSA ST59 MRSA-IVa “USA1000” control strain
(NARSA483). Both strains have acquired seb, sek, and seq
enterotoxin genes and lack antimicrobial resistance genes
apart from mecA and blaZ.
Group 2, “WA MRSA-24” (PVL-negative ST87 MRSA-IVb
[2B]). Three “WA MRSA-24” isolates (04-17626, 06-15325,
and 06-16824), collected from unrelated patients in 2004 and
2006, were identified as ST87 (an SLV of ST59 [59SLV])/spa
type t216 with a type IVb (2B) SCCmec. The beta-lactamase
operon (blaZ, blaI, and blaR), the msrA, mpbBM (macrolide),
aphA3 (neomycin), and sat (streptothricin) resistance genes,
FIG. 1. Representative pulsed-field gel electrophoresis patterns of the seven Western Australian CC59 MRSA strains.
FIG. 2. SplitsTree graph visualizing similarities of CC59 isolates and strains based on hybridization results for mecA, mecR, ugpQ, the dcs
region, ccrA2, ccrB2, 85-2082 ccrC1, hypothetical ORF accompanying ccrC1, blaZ, blaI, blaR, ermB, ermC, msrA, mpbBM, aphA3, sat, tetK, pC221
cat, pC223 cat, sea, seb, sek, seq, lukF-PV, lukS-PV, and sak (Table 2). Isolate designations in boxes indicate PVL-positive isolates.
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and the seb, sek, and seq enterotoxin genes were present in all
three isolates. The isolates were also positive for staphyloki-
nase (sak), chemotaxis-inhibiting protein (chp), and staphylo-
coccal complement inhibitor (scn) genes, which are known to
be located on beta-hemolysin integrating phages. However, the
enterotoxin A (sea) gene, which is also located on beta-hemo-
lysin integrating phages, was not detected. PVL was not de-
tected.
Group 3, “WA MRSA-55/56” (PVL-variable ST59 MRSA-IV
[2B], structural subtypes IVa, IVd, and IVv). Group 3, a group
of seven ST59/spa type t437 isolates, is comprised of four very
similar strains that have acquired ermB (macrolide-lincos-
amide-streptogramin B), aphA3, sat, and tetK resistance genes.
In this regard, they resemble the “Taiwan clone” (see below).
The other three strains in this group differ by variable carriage
of PVL and enterotoxin A (sea) and SCCmec type IV subtype.
The first strain, PVL-positive “WA MRSA-55,” included
four isolates (06-16367, 06-17947, 07-15432, and 07-15760) col-
lected in 2006 and 2007. All four isolates harbored an SCCmec
IVa (2B) element, and their DNA microarray-based profiles
were identical. The beta-lactamase operon (blaZ, blaI, and
blaR), ermB, aphA3, sat, and tetK resistance genes as well as the
seb, sek, and seq enterotoxin genes, PVL genes (lukF-PV and
lukS-PV), and chp, scn, and sak genes were all detected in this
strain.
The second strain (08-16180) was also PVL positive and,
except for the absence of the sak gene and the presence of the
chloramphenicol resistance gene cat, yielded the same DNA
microarray hybridization pattern as the first strain in this
group. However, SCCmec analysis by PCR revealed that this
isolate harbored a type IVd (2B) SCCmec element.
The third strain, a PVL-negative isolate (08-17668), closely
resembled the PVL-positive strain “WA MRSA-55” in terms
of microarray hybridization and PFGE pattern. However, it
has acquired a novel type IV (2B) SCCmec which could not be
subtyped with primers specifying subtypes a to h.
The fourth strain, “WA MRSA-56,” consisted of one iso-
late (07-15443) collected in 2007. It was also identified as
PVL-positive ST59 MRSA-IVa (2B). However, unlike the
other group 3 strains, “WA MRSA-56” carried the entero-
toxin gene sea.
Group 4, “WA MRSA-15” (PVL-negative ST59 MRSA-IVa
[2B&5]). Group 4 consisted of nine isolates (03-17565, 04-
16557, 04-17489, 05-17037, 05-17619, 06-15513, 06-17484, 07-
19251, and 08-15202) collected from seven individual patients
between 2003 and 2008. One patient with various wound in-
fections yielded three identical isolates in three subsequent
years (2004 to 2006).
These isolates were identified as PVL-negative ST59
MRSA-IVa (2B&5) (ccrA2B2 mec complex class B and
ccrC1)/spa type t976.
All nine isolates carried the beta-lactamase operon (blaZ,
blaI, and blaR). Variable resistance genes, including msrA and
mpbBM (in two isolates), aphA3 and sat (in one isolate), and
tetK (in one isolate), were detected. All isolates were negative
for PVL genes but positive for the enterotoxin A gene (sea).
Seven out of nine isolates harbored seb, sek, and seq entero-
toxin genes.
Isolate 05-17037 differed in its carriage of resistance genes
(msrA, mpbBM, aphA3, sat, and tetK). DNA microarray-based
markers indicated that all isolates in this group encoded an
unusual SCCmec element with mec complex class B and ccr
complex type 2, characteristic of SCCmec type IV, and ccrC1,
which has thus far been found in SCCmec type V or SCC
elements. Positive hybridization signals for SCCmec markers
mecA, mecR, ugpQ, the dcs region, ccrA2, ccrB2, 85-2082
ccrA, and 85-2082 ccrC1 were obtained. SCCmec PCR con-
firmed this observation. All isolates in the group were positive
for SCCmec type IVa (2B) structural elements, and all en-
coded a class B mec complex, a type 2 ccr complex, and ccrC1
allele 2. This suggests either the presence of a composite IVa
(2B) and V (5C2) SCCmec element or the additional presence
of an SCC element encoding ccrC1 allele 2.
Group 5, “WA MRSA-9/52,” or “Taiwan clone” (PVL-posi-
tive ST59/338/952 MRSA-V [5C2&5]). Group 5 consisted of 17
“WA MRSA-9” isolates identified as ST59/spa type t437, t441,
or t2365 and three “WA MRSA-52” isolates identified as
ST952 (a single-locus variant of ST59)/spa type t1950 (Table
1). The DNA microarray-based profiles for these 20 isolates
were similar, and consequently the two strains were classified
into one group. “WA MRSA-9” was the first SCCmec V
(5C2&5) (mec complex class C2 and ccrC1) CC59 strain found
in Western Australia (in 2003), and it appears to be the most
common and clinically relevant strain in this clonal complex.
For SCCmec markers on the array, all isolates yielded hy-
bridization signals with probes for mecA, ugpQ, 85-2082 ccrA,
and MRSAZH47 ccrA, as well as for ccrC1. When tested by
PCR, all 20 strains had mec complex C2 and ccrC1. ccrC1
allotyping revealed the presence of two ccrC1 complexes,
ccrC1 allele 2 and ccrC1 allele 8, which is characteristic of the
SCCmec encoded by the Taiwan clone. An ISSau4-like trans-
posase was found inserted into the structural gene V011 of all
isolates in this group.
All 20 “Taiwan clone” isolates carried the beta-lactamase
operon (blaZ, blaI, and blaR) as well as ermB, aphA3, and sat.
Variable resistance genes were tetK (in 14 isolates) and cat (in
17 isolates). All isolates were positive for lukF-PV and lukS-PV.
Enterotoxin genes seb, sek, and seq were present in 15 of the 20
isolates.
Group 6, “WA MRSA-9” (PVL-negative ST59 MRSA-Vv
[5C2]). Although characterized as “WA MRSA-9” by PFGE,
three isolates (05-17759, 08-15683, and 06-18653) were classi-
fied into group 6. These isolates carried an SCCmec type V
variant (5C2) (ccrC1 and mec complex class C2) element.
However, they yielded a DNA hybridization pattern different
from that of the “Taiwan clone” (group 5). They were positive
for mecA, ugpQ, 85-2082 ccrA, and 85-2082 ccrC1 but negative
with the MRSAZH47 ccrA probe.
PCR SCCmec analysis revealed that isolates from this group
did not amplify the SCCmec type V (5C2) specific structural
ORF V011 (GenBank accession no. AB12129) with or without
the ISSau4-like transposase insertion. However, they were pos-
itive for the type V (5C2) core genes for mec complex C2 and
ccrC1. Allotyping of the ccrC1 gene revealed that it was neither
allele 2 nor allele 8. On the basis of a lack of amplification of
the structural gene, the SCCmec of these strains has been
classified as a type V variant (Vv [5C2]). It is evident that this
group of isolates harbors an SCCmec element that is signifi-
cantly different from that of the Taiwan clone.
Two isolates carried the beta-lactamase operon, and one was
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positive for ermC (macrolide-lincosamide resistance) and cat.
All three isolates harbored seb, sek, and seq enterotoxin genes
as well as chp and scn. One isolate also yielded hybridization
signals for the staphylokinase gene sak. All isolates were PVL
negative.
DISCUSSION
In Western Australia there are at least six discernible groups
of CC59 CA-MRSA strains, which can be differentiated by
PFGE, MLST, determination of the presence or absence of
PVL, determination of the SCCmec type, or microarray anal-
ysis. Within the study strains, at least seven different variants of
SCCmec elements (IVa [2B], IVb [2B], IVd [2B], IVa [2B&5],
IVv [2B], Vv [5C2], and V [5C2&5]) were distinguished. This
suggests rapid evolution and/or multiple transfer events of
SCCmec elements. In a recent study by Takano et al. (24), at
least six SCCmec elements were described to occur in a col-
lection of ST59 MRSA strains isolated in Taiwan, including V
(5C), V (5C2&5), IVc (2B), IV (2B), and two novel elements.
This diversity of SCCmec types and subtypes can be expected
to cause ambiguities in nomenclature, which underscores
the need for sequence information. Consequently, the novel
SCCmec elements described in this study warrant further
characterization, although sequencing is beyond the scope of
this study. Another observation suggesting a rapid evolution
within CC59 is that groups 3 and 5 (“Taiwan clone”) appear to
be closely related to each other with regard to all markers but
SCCmec. Both groups share aphA3, sat, ermB, and usually also
cat as well as PVL. This indicates that groups 3 and 5 might
represent one branch of the CC59 complex that evolved into
separate groups by acquiring different SCCmec elements. Gen-
erally, CC59 displayed a high degree of variability, affecting not
only SCCmec markers but also a variety of other mobile
genetic elements. For instance, “USA1000” and “WA MRSA-
73” differ only in the presence of PVL. It cannot yet be deter-
mined whether “USA1000” evolved from a “WA MRSA-73”-
like ancestor by acquiring PVL, whether “WA MRSA-73” was
a deletion variant of USA1000, or whether both represent
independently evolved branches of one lineage. Similarly, iso-
late 08-17668 might represent either a PVL-negative ancestor
or a mere deletion mutant of group 3 strains. A high degree of
variability can also be detected within CC59 groups. For ex-
ample, the Taiwan clone (group 5) can be subdivided based on
resistance and toxin genes and spa and MLST sequences. Such
variation within a supposed “clone” might be used to trace
individual chains of infection, as in the case of the patients with
the ST952 variant of the “Taiwan clone” (“WA MRSA-52”)
who belonged to the same family.
Further studies should investigate the variability and evolu-
tion of CC59 strains in other locations where this clonal com-
plex has been detected. Apart from data for the Taiwan clone
(group 5), there are little data available on the distribution of
CC59 clones outside Western Australia. It can be assumed that
these strains are usually identified as “USA1000” or the “Tai-
wan clone” and that their true diversity remains unrecognized.
This might also obscure routes of transmission of CC59 CA-
MRSA strains and hinder the understanding of their interna-
tional spread.
If a variety of closely related strains exist simultaneously, it
can be assumed that they are in competition with each other
for “ecological” resources, i.e., for susceptible, as yet uncolo-
nized hosts. The ecological success of strains should result in
wide distribution and/or relatively high prevalence. The Tai-
wan clone (group 5) could be regarded as the most successful
strain among the CC59 CA-MRSA strains isolated in Western
Australia. In our study, nearly as many isolates belonged to
group 5 as to all other CC59 groups combined. Since the
groups are nearly isogenic, a marker determining such success
should be found among the rather limited number of genes
which are variable within CC59, and it should be present in the
Taiwan clone. Full genome sequencing of representative
strains of CC59 may provide the answer and overcome the
limitations of this study. Among the genes which were exam-
ined in this study, PVL genes could be related to the success of
the Taiwan clone.
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